Special report: vaccines for the treatment of malignant melanoma

BlueCross BlueShield Association
Record ID 32003000738
Authors' objectives:

The specific objectives of this special report are informational in nature, as follows:

- to review the immunologic principles supporting the development of a melanoma vaccine; - to review the various biologic approaches being taken to develop a melanoma vaccine, especially those that have resulted in phase III trials; - to review the results of completed phase III trials of melanoma vaccines, and to summarize active and recently closed phase III trial protocols; - to summarize and evaluate the evidence from phase I/II trials of those melanoma vaccines currently in phase III trials.

Authors' methods: Systematic review
Project Status: Completed
Year Published: 2001
English language abstract: An English language summary is available
Publication Type: Not Assigned
Country: United States
MeSH Terms
  • Vaccination
  • Melanoma
  • Skin Neoplasms
Organisation Name: BlueCross BlueShield Association
Contact Address: BlueCross BlueShield Association, Technology Evaluation Center, 225 North Michigan Ave, Chicago, Illinois, USA. Tel: 888 832 4321
Contact Name: tec@bcbsa.com
Contact Email: tec@bcbsa.com
Copyright: BlueCross BlueShield Association (BCBS)
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.